SEC Form 4 · accession 0001571049-16-019927
Bellerophon Therapeutics, Inc. · BLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fabian Tenenbaum
Officer — Chief Executive Officer
Period of report
Nov 11, 2016
Accepted (ET)
Nov 15, 2016 · 5:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001600132
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.98 | Nov 11, 2016 | A | 466,141 | A | — | Nov 11, 2026 | Common Stock | 466,141 | 466,141 | D |
Explanation of responses
- F1This option was granted on November 11, 2016. This option vests in four equal installments over a four-year period from the date of grant, with the first installment vesting on the date that is one year following the date of the grant.